hi O&E, in very simple terms, the point of Renovo's TAMP platform is to allow drugs (including, potentially CF33) to be targeted onto tumours that are not directly fed by blood vessels. For those tumors, intravenously delivered drugs are less effective. Hence the Imugene-Renovo collab will (hopefully) demonstrate how good CF33 can infect tumors which are not easily accessible via IT or IV.
Media Thread, page-14993
-
- There are more pages in this discussion • 443 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.4¢ |
Change
-0.002(3.57%) |
Mkt cap ! $401.6M | |||
| Open | High | Low | Value | Volume |
| 5.6¢ | 5.7¢ | 5.4¢ | $1.182M | 21.47M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 32 | 3441484 | 5.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.5¢ | 574188 | 6 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| IMU (ASX) Chart |